Preclinical Rationale, Clinical Efficacy, and Safety of the Selective AKT Kinase Inhibitor Capivasertib in Metastatic Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Carcinoma: A Practical Narrative Review.
Simple Summary: Capivasertib is a selective AKT kinase inhibitor recently approved for the treatment of estrogen receptor-positive/HER2-negative advanced BC with alterations of the PIK3CA/AKT1/PTEN pathway, in combination with fulvestrant after progression on endocrine therapy. In this review we sum...
| Publicado en: | Current Oncology Vol. 33; no. 4; pp. 198 - 218 |
|---|---|
| Autores principales: | , , , , , , , |
| Formato: | Journal Article |
| Publicado: |
MDPI
Apr2026
|
| Acceso en línea: | Ver este registro en EBSCOhost |